L Lai Lab · 賴峻毅實驗室
Featured 03 selected · 2024–2025

Recent highlights.

2024 · Phase III

Abemaciclib plus fulvestrant in advanced breast cancer following progression on CDK4/6 inhibition.

Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Muñoz M, Lai JI, Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA.
Results from the Phase III postMONARCH Trial — Journal of Clinical Oncology, 2024
JCO · 10.1200/JCO-24-02086 DOI →
2025 · Original

HDAC inhibitors modulate Hippo pathway signaling in hormone-positive breast cancer.

Lin TI, Tseng YR, Dong MJ, Lin CY, Chung WT, Liu CY, Tsai YF, Huang CC, Tseng LM, Chao TC, Lai JI.
Clinical Epigenetics, 2025
Accepted DOI →
2025 · Original

Bevacizumab + vinorelbine-platinum in heavily pretreated HER2-negative metastatic breast cancer.

Ho IW, Tseng YR, Liu CY, Tsai YF, Huang CC, Tseng LM, Chao TC, Lai JI.
J Cancer 2025; 16(5):1726-1735
doi:10.7150/jca.105199 DOI →
2025 · Translational NEPC

Real-world treatment outcomes and genomic insights for metastatic prostate neuroendocrine carcinoma.

Lai JI, Peng YC, Chang PM, Chang YH, Chung HJ, Huang YH, Lin TP, Huang WJ, Wei TC, Huang TH, Yen CC.
Journal of the Chinese Medical Association, Jan 2025
first author DOI →
2023 · Clinical

Clinical and genotypic insights into higher prevalence of palbociclib-associated neutropenia in Asian patients.

Lai JI, Kuo TH, Huang KJ, Chai LMX, Lee MH, Liu CY, Tsai YF, Huang CC, Tseng LM, Hsu CC, Chao TC.
Oncologist, 2023
corresponding DOI →

Publications after 2017

1
HDAC inhibitors modulate Hippo pathway signaling in hormone-positive breast cancer.
Lin TI, Tseng YR, Dong MJ, Lin CY, Chung WT, Liu CY, Tsai YF, Huang CC, Tseng LM, Chao TC, Lai JI.
Clinical Epigenetics. 2025 Feb 26;17(1):37
2025
corr
2
Patients' and doctors' preferences in early-stage triple-negative breast cancer treatment in Asia-Pacific: a multi-territory discrete choice experiment using a cross-sectional survey.
Lai JI, Jung KH, Shimizu C, Tiambeng ML, Tseng LM, Hsu DC, Ihm SY, Spiteri C, Tan EM, Qu S, Antill Y.
BMJ Open. 2025 Mar 3;15(3):e088505
2025
first
3
Addition of bevacizumab to vinorelbine-platinum combination is efficacious in heavily pretreated HER2-negative metastatic breast cancer.
Ho IW, Tseng YR, Liu CY, Tsai YF, Huang CC, Tseng LM, Chao TC, Lai JI.
J Cancer. 2025;16(5):1726-1735
2025
corr
4
Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma.
Lai JI, Peng YC, Chang PMH, Chang YH, Chung HJ, Huang YH, Lin TP, Huang WJ, Wei TC, Huang TH, Yen CC.
Journal of the Chinese Medical Association. 2025 Jan 17
2025
first
5
Clinical and genotypic insights into higher prevalence of palbociclib-associated neutropenia in Asian patients.
Lai JI, Kuo TH, Huang KJ, Chai LMX, Lee MH, Liu CY, Tsai YF, Huang CC, Tseng LM, Hsu CC, Chao TC.
The Oncologist. 2024 Apr 4;29(4):e455-e466
2024
first
6
A systemic review of taxanes and their side effects in metastatic breast cancer.
Lai JI, Chao TC, Liu CY, Huang CC, Tseng LM.
Frontiers in Oncology. 2022 Oct 11;12:940239
2022
first
7
IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target.
Lin CY, Yu CJ, Shen CI, Liu CY, Chao TC, Huang CC, Tseng LM, Lai JI.
Medical Oncology. 2022 Sep 30;39(12):242
2022
corr
8
CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin-proteasome pathway in ER+ breast cancer.
Lin CY, Yu CJ, Liu CY, Chao TC, Huang CC, Tseng LM, Lai JI.
Clinical and Translational Oncology. 2022 Aug 2
2022
corr
9
Clinical perspective of FDA-approved drugs with P-glycoprotein inhibition activities for potential cancer therapeutics.
Lai JI, Tseng YJ, Chen MH, Huang CF, Chang PM.
Frontiers in Oncology. 2020 Nov 16;10:561936
2020
first
10
Concomitant genetic alterations are associated with worse clinical outcome in EGFR-mutant NSCLC patients treated with tyrosine kinase inhibitors.
Chang SC, Lai YC, Chang CY, Huang LK, Chen SJ, Tan KT, Yu PN, Lai JI.
Translational Oncology. 2019 Aug;12(11):1425-1431
2019
corr
11
High-grade salivary gland ductal carcinoma with unusual EGFR amplification responsive to afatinib.
Lai JI, Reddy AK, Newberg JY, Montesion M, Chang PMH.
JCO Precision Oncology. 2019 Dec;3:1-5
2019
first
12
Impact of angiotensin I converting enzyme gene I/D polymorphism on running performance, lipid, and biochemical parameters in ultra-marathoners.
Chiu YH, Lai JI, Tseng CY, Wang SH, Li LH, Kao WF, How CK, Chang WH, Hsieh CY.
Medicine (Baltimore). 2019 Jul;98(29):e16476
2019
co-first
13
Transcriptional profiling of isogenic Friedreich ataxia neurons and effect of an HDAC inhibitor on disease signatures.
Lai JI, Nachun D, Petrosyan L, Throesch B, Campau E, Gao F, Baldwin KK, Coppola G, Gottesfeld JM, Soragni E.
Journal of Biological Chemistry. 2019 Feb 8;294(6):1846-1859
2019
first
14
Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation.
Lai JI, Lai YC, Chen YC, Wang NK, Pan JN, Wang WS, Chang SC.
Cancer Gene Therapy. 2017 Sep;24(9):373-380
2017
first
15
Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: screening with iPSC-derived neuronal cells.
Lai JI, Leman LJ, Ku S, Vickers CJ, Olsen CA, Montero A, Ghadiri MR, Gottesfeld JM.
Bioorganic & Medicinal Chemistry Letters. 2017 Aug 1;27(15):3289-3293
2017
first
16
CBX3/heterochromatin protein 1 gamma is significantly upregulated in patients with non-small cell lung cancer.
Chang SC, Lai YC, Chen YC, Wang NK, Pan JN, Wang WS, Lai JI.
Asia-Pacific Journal of Clinical Oncology. 2017 Nov 10
2017
corr
In partnership with NYCU · Taipei Veterans General Hospital · Comprehensive Breast Health Center